CJC-1295 vs GHRP-6
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
CJC-1295
CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog. It stimulates the pituitary gland to release growth hormone and is almost universally used in combination with a GHRP like Ipamorelin to produce a more physiological GH pulse.
Full profileGHRP-6
GHRP-6 is a first-generation synthetic hexapeptide GH secretagogue that strongly stimulates pituitary GH release via ghrelin receptor activation. It is one of the oldest and most well-studied GHRPs, with a large body of research spanning more than three decades. GHRP-6 produces significant GH pulses but is notable for powerfully stimulating appetite — a side effect that can be beneficial for those in a caloric deficit or disadvantageous for those managing body composition.
Full profile| CJC-1295 | GHRP-6 | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | CJC-1295 DAC, CJC-1295 without DAC (Mod GRF 1-29), Modified GRF 1-29 | Growth Hormone Releasing Peptide-6, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 |
| Evidence | Research-stage | Preclinical only |
| Dosing range | 100mcg–300mcg mcg, once daily (Mod GRF) or twice weekly (DAC version) | 100mcg–300mcg mcg, 1–3 times daily, on an empty stomach |
| Administration | Subcutaneous injection (most common), Intramuscular injection | Subcutaneous injection, Intramuscular injection |
| Key side effects | Water retention (especially early in protocol), Tingling or numbness in extremities, Injection site redness, Flushing (transient, shortly after injection) | Strong increase in appetite (most common and notable), Elevated cortisol and prolactin at higher doses, Water retention / bloating, Fatigue at high doses |
| Cited sources | 2 references | 3 references |
Key differences
- Evidence level differs: CJC-1295 is research-stage, while GHRP-6 is preclinical only.
- Administration: CJC-1295 — Subcutaneous injection (most common), Intramuscular injection; GHRP-6 — Subcutaneous injection, Intramuscular injection.
- Frequency: CJC-1295 is typically once daily (Mod GRF) or twice weekly (DAC version); GHRP-6 is 1–3 times daily, on an empty stomach.
- Research depth: this profile cites 2 sources for CJC-1295 vs 3 for GHRP-6.
How each works
CJC-1295
Studies have demonstrated that CJC-1295 significantly increases plasma GH and IGF-1 levels. The DAC (Drug Affinity Complex) version extends the half-life to approximately 6–8 days via albumin binding, while Mod GRF 1-29 has a much shorter half-life (~30 minutes) and is dosed more acutely. Research in adults with GH deficiency has shown improved body composition and metabolic markers.
GHRP-6
Human studies confirm GHRP-6 robustly elevates GH within 15–30 minutes of injection, with effects diminishing toward baseline within 2–3 hours. Chronic use increases baseline IGF-1. Research also indicates mild stimulation of cortisol and prolactin, particularly at higher doses. Animal models have shown potential cardioprotective, hepatoprotective, and muscle-sparing effects, though human equivalents are not established.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.